 | | Vol. 10.35 – 7 September, 2022 |
| |
|
|
| Researchers used amino acid restriction, metabolomic, and CRISPR approaches to identify that an abundant methionine supply and interconnecting methionine and folate cycles maintained Burkitt Epstein-Barr virus (EBV) gene silencing.
[Cell Metabolism] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists conducted a multiomics study of SARS-CoV-2-infected lung epithelial cells, including transcriptomic, proteomic, and ubiquitinomic.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators used whole-metagenome shotgun sequencing data together with assembly and binning strategies to reconstruct metagenome-assembled genomes from 514 COVID-19 related nasopharyngeal and fecal samples in six independent cohorts.
[Nature Communications] |
|
|
|
| Using real-time 3D single-virion tracking, the authors showed that fusion and genome penetration required virion exposure to an acidic milieu of pH 6.2 to 6.8, even when furin and TMPRSS2 cleavages had occurred.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers identified several highly conservative and stable G4s in SARS-CoV-2 and clarified their dual-function of inhibition of the viral replication and translation processes.
[Cell Discovery] |
|
|
|
| Investigators found that a new invariant natural killer T (iNKT)-cell agonist αGC-CPOEt elicited a strong cytokine response with increased IL-4 production.
[ACS Infectious Diseases] |
|
|
|
| Scientists analyzed SARS-CoV-2 reactive T cell responses in 768 convalescent SARS-CoV-2-infected and 500 uninfected Icelanders.
[Communications Biology] |
|
|
|
| The authors performed in silico analysis to search for novel immunogenic and antigenic peptides. A total of twenty-five peptides were preliminarily selected, located in the 3D structure of the spike and nucleocapsid proteins.
[Scientific Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Investigators showed that mice lacking von Hippel-Lindau factor in T cells were highly susceptible to infection with M. tuberculosis, which was associated with a low accumulation of mycobacteria-specific T cells in the lungs that displayed reduced proliferation, altered differentiation, and enhanced expression of inhibitory receptors.
[Nature Communications] |
|
|
|
| Researchers reported a strategy to enrich clones of latent cells carrying intact, replication-competent HIV-1 proviruses from blood based on their expression of unique T cell receptors.
[Cell Reports] |
|
|
|
| The authors showed that the production and degradation of cyclic diadenosine monophosphate (c-di-AMP) were necessary during different phases of C. difficile growth, environmental adaptation, and infection.
[Science Signaling] |
|
|
|
| Scientists demonstrated that deficiency of triggering receptors expressed on myeloid cells 2 (TREM2) significantly enhanced macrophage pyroptosis induced by four common pyogenic bacteria including Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae, and Escherichia coli.
[Cell Death & Disease] |
|
|
|
| Researchers designed a recombinant reporter arenavirus lymphocytic choriomeningitis virus that stably expressed nanoluciferase.
[iScience] |
|
|
|
|
| The authors discuss the clinical, epidemiological, and immunological features of Monkeypox virus infections.
[Nature Reviews Immunology] |
|
|
|
| Post-acute sequelae of SARS-CoV-2 represents a formidable challenge for health care systems and dissecting pathogenetic mechanisms may pave the way to targeted preventive and therapeutic approaches.
[Cell Death & Differentiation] |
|
|
|
|
| Evaxion Biotech A/S, announced that the company, in collaboration with UMass Chan Medical School, has received a grant from the US NIH for the development of a gonorrhea lead vaccine candidate.
[Evaxion Biotech A/S] |
|
|
|
| Australia’s largest-ever philanthropic donation for medical research will fund a new center dedicated to laying the groundwork for developing therapies to fight future pandemics, the Peter Doherty Institute for Infection and Immunity recently announced.
[The Scientist] |
|
|
|
| Emergent BioSolutions, Inc. announced that it has dosed the first participant in its Phase I study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection.
[Emergent BioSolutions, Inc.] |
|
|
|
|
| September 30, 2022
Clayton, Victoria, Australia |
|
|
|
|
|
| | Rutgers New Jersey Medical School – Rutgers, New Jersey, United States |
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | Melanoma Institute Australia – Sydney, Australia |
|
|
|
| | Technical University of Denmark – Lyngby, Denmark |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
